Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Economy of Denmark Statistics Denmark Danmarks Nationalbank – central bank of Denmark OECD's Denmark country Web site and OECD Economic Survey of Denmark Bureau of Public Affairs, U.S. Department of State, country overview for Denmark World Bank Summary Trade Statistics Denmark Dansk Arbejdsgiverforening Confederation of Danish Employers Landsorganisationen i Danmark The Danish Confederation of Trade Unions Anvendt Kommunal Forskning Danish Institute of Governmental Research The Danish National Centre for Social Research De økonomiske Råds sekretariat Danish Economic Councils Archived 17 March 2015 at the Wayback Machine Economic Council of the Labour Movement CEPOS Think Tank for a liberal economy and limited Government etc. Center for Alternativ Samfundsanalyse Centre for Alternative Social Analysis Economic History Services Encyclopedia: Denmark Danish Top 1000 Companies[link removed] The World Factbook: Economy:Denmark
A wide range of applications have been demonstrated for AMMs, including those integrated into polymeric, liquid crystal, and crystalline systems for varied functions (such as materials research, homogenous catalysis and surface chemistry).
8 January Mondelez International announces plans to celebrate the bicentenary 200th Anniversary of Cadbury. Chinese authorities say they have detained an individual who they allege has been working for the British Secret Intelligence Service MI6. Ofgem grants permission for energy companies to resume the forced installation of prepayment meters a year after the practice was suspended and after drawing up new rules that prohibits them being installed under certain conditions, such as households where the occupant is over 75, where there are children under two, and for those with certain health conditions. At an event held in Parliament Square, the actor Idris Elba calls on the UK government to introduce an immediate ban on the sale of zombie knives and machetes to reduce the number of young people losing their lives because of the weapons. London and the south-east see a mix of snow, sleet, and rain as the country braces for a week-long cold spell. British Post Office scandal: More than a million people have signed a petition calling for former Post Office chief executive Paula Vennells to be stripped of her CBE in the wake of the Horizon IT scandal. Labour Party leader Keir Starmer, who was Director of Public Prosecutions during the scandal, faces questions over why he failed to intervene in the prosecution of innocent sub-postmasters at the time. 9 January Economists say that funding the student loans system in England is expected to cost the government an extra £10 billion a year.
=== Cancers === Lung cancer can either arise directly from lung tissue or as a result of metastasis from another part of the body. There are two main types of primary tumour described as either small-cell or non-small-cell lung carcinomas. The major risk factor for cancer is smoking. Once a cancer is identified it is staged using scans such as a CT scan and a sample of tissue from a biopsy is taken. Cancers may be treated surgically by removing the tumour, the use of radiotherapy, chemotherapy or a combination, or with the aim of symptom control. Lung cancer screening is being recommended in the United States for high-risk populations.
Sources: en.wikipedia.org
In October 2014, Shankar announced the production of an unofficial spin-off online series based on the Dark Judges that would be released later that month. The animated miniseries was titled Judge Dredd: Superfiend and all its six episodes were released on 27 October 2014 on YouTube. In March 2015, Garland said that a direct sequel would likely not happen in the near future, at least not with the crew involved in the original film. In 2016, Urban said that "conversations are happening" regarding a Dredd continuation on streaming services Netflix or Amazon Prime. In an interview in May 2016, Urban said that while the film's "mishandled" marketing strategy and "unfortunate" box office performance meant that it was "problematic" to try to make a sequel, "the success it has achieved in all post-theatrical mediums has definitely strengthened the argument in favour of a sequel." In May 2017, a television series named Judge Dredd: Mega-City One was announced to be in development by IM Global Television and Rebellion. In August 2017, Urban stated he was in discussion to star in the series. The series was eventually put on hold due to the pandemic back in 2020. Rebellion CEO Jason Kingsley explained to Radio Times back in 2020, "I want there to be a sequel [to Dredd]. We've got the rights back so we can do it, we've just got to get rid of this virus thing that's going on at the moment, and then hopefully things can kick off in all sorts of different areas of making film and TV, it's just– it's all very messed up at the moment for everybody".
=== Metabolic panel === A Metabolic Panel (MP) is a routine group of blood tests commonly used for health screenings, disease detection, and monitoring vital signs of hospitalized patients with specific medical conditions. MP panel analyzes common analytes in the blood to assess the functions of the kidneys and liver, as well as electrolyte and acid-base balances. There are two types of MPs - Basic Metabolic Panel (BMP) or Comprehensive Metabolic Panel (CMP).
=== Indication differences === Agents specifically labeled for cardiac arrhythmia Esmolol, sotalol, landiolol (Japan) Agents specifically labeled for congestive heart failure Bisoprolol, carvedilol, sustained-release metoprolol Agents specifically labeled for glaucoma Betaxolol, carteolol, levobunolol, timolol, metipranolol Agents specifically labeled for myocardial infarction Atenolol, metoprolol (immediate release), propranolol (immediate release), timolol, carvedilol (after left ventricular dysfunction), bisoprolol (preventive treatment before and primary treatment after heart attacks) Agents specifically labeled for migraine prophylaxis Timolol, propranolol Propranolol is the only agent indicated for the control of tremor, portal hypertension, and esophageal variceal bleeding, and used in conjunction with α-blocker therapy in phaeochromocytoma.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.